Hologic, Inc. (HOLX) EBITDA Margin: 24.97%
Is Hologic, Inc.’s EBITDA margin high or low?
Hologic, Inc.'s EBITDA margin of 24.97% is 31% below its 5-year average of 36.42%, near the low end of its 5-year range (24.97%–50.81%).
The EBITDA margin for Hologic, Inc. (HOLX) is 24.97% as of Wednesday, June 10, 2026. It is below its 12-month average by 12.59% (28.56%).
HOLX EBITDA Margin Chart
HOLX Average EBITDA Margin Chart
HOLX Current vs Average EBITDA Margin Chart
HOLX EBITDA Margin Metrics
EBITDA MARGIN
24.97%
EBITDA MARGIN AVG TTM
28.56%
EBITDA MARGIN AVG 3Y
32.04%
EBITDA MARGIN AVG 5Y
36.42%
EBITDA MARGIN AVG 10Y
33.10%
EBITDA MARGIN AVG 15Y
28.67%
EBITDA MARGIN AVG 20Y
19.25%
CURRENT VS TTM AVG
-12.59%
CURRENT VS 3Y AVG
-22.06%
CURRENT VS 5Y AVG
-31.44%
CURRENT VS 10Y AVG
-24.57%
CURRENT VS 15Y AVG
-12.91%
CURRENT VS 20Y AVG
+29.69%
HOLX Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | $16.97B | 24.97% | 28.56% | 32.04% | 36.42% |
| Moderna, Inc. (MRNA) | $18.40B | -131.33% | -118.72% | -58.41% | -40.82% |
| Align Technology, Inc. (ALGN) | $12.56B | 18.98% | 19.70% | 20.24% | 21.31% |
| BioNTech SE (BNTX) | $21.81B | -9.29% | -11.31% | 22.27% | 24.39% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 30.67% | 31.14% | 31.31% | 30.59% |
| Baxter International Inc. (BAX) | $10.49B | 6.81% | 8.65% | 4.13% | 9.00% |
| Waters Corporation (WAT) | $23.83B | 31.97% | 33.50% | 33.77% | 33.93% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 22.69% | 18.52% | 21.71% | 22.71% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 18.42% | -32.52% | -62.43% | 23.50% |
| Veeva Systems Inc. (VEEV) | $26.73B | 28.68% | 27.64% | 24.37% | 25.68% |
Margin Comparison
Gross Margin
52.8%
EBITDA Margin
25.0%
Operating Margin
17.5%
Net Margin
13.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Hologic, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Hologic, Inc. (HOLX)?
- The EBITDA margin for HOLX stock is 24.97%.
- Is Hologic, Inc.'s EBITDA margin high or low?
- Hologic, Inc.'s EBITDA margin of 24.97% is 31% below its 5-year average of 36.42%, near the low end of its 5-year range (24.97%–50.81%).
- What is the TTM average EBITDA margin for Hologic, Inc. (HOLX)?
- The TTM average EBITDA margin for HOLX stock is 28.56%.
- What is the 3Y average EBITDA margin for Hologic, Inc. (HOLX)?
- The 3Y average EBITDA margin for HOLX stock is 32.04%.
- What is the 5Y average EBITDA margin for Hologic, Inc. (HOLX)?
- The 5Y average EBITDA margin for HOLX stock is 36.42%.
- What is the 10Y average EBITDA margin for Hologic, Inc. (HOLX)?
- The 10Y average EBITDA margin for HOLX stock is 33.10%.
- What is the 15Y average EBITDA margin for Hologic, Inc. (HOLX)?
- The 15Y average EBITDA margin for HOLX stock is 28.67%.
- What is the 20Y average EBITDA margin for Hologic, Inc. (HOLX)?
- The 20Y average EBITDA margin for HOLX stock is 19.25%.
Hologic, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-09-27 | 24.97% |
| 2024-09-30 | 32.16% |
| 2023-09-30 | 27.56% |
| 2022-09-30 | 43.46% |
| 2021-09-30 | 50.81% |
| 2020-09-30 | 39.57% |
| 2019-09-30 | 10.28% |
| 2018-09-30 | 6.54% |
| 2017-09-30 | 59.92% |
| 2016-09-30 | 36.57% |
| 2015-09-30 | 32.31% |
| 2014-09-30 | 31.29% |
| 2013-09-30 | -15.88% |
| 2012-09-30 | 21.19% |
| 2011-09-30 | 36.16% |
| 2010-09-30 | 21.84% |
| 2009-09-30 | -106.60% |
| 2008-09-30 | -1.27% |
| 2007-09-30 | 24.23% |
| 2006-09-30 | 15.25% |
| 2005-09-30 | 13.98% |
| 2004-09-30 | 8.82% |
| 2003-09-30 | 1.48% |
| 2002-09-30 | 6.15% |
| 2001-09-30 | -4.79% |
| 2000-09-30 | -24.47% |
| 1999-09-30 | -7.25% |
| 1998-09-30 | 10.99% |
| 1997-09-30 | 22.21% |
| 1996-09-30 | 20.75% |
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini